Overview

This trial is active, not recruiting.

Condition end stage renal disease
Treatments envarsus®, prograf®, advagraf®
Phase phase 4
Sponsor Chiesi Farmaceutici S.p.A.
Start date May 2015
End date February 2017
Trial size 445 participants
Trial identifier NCT02432833, 2014-004314-29, CCD-06235AA1-01

Summary

The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
prolonged-release tablets once daily and orally
envarsus®
Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
(Active Comparator)
Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
prograf®
Prograf® hard capsules, twice daily, oral formulation
advagraf®
Advagraf® prolonged-release hard capsules, once daily, oral formulation

Primary Outcomes

Measure
Tacrolimus total daily dose (TDD) from week 3 to month 6
time frame: from week 3 to month 6

Secondary Outcomes

Measure
Tacrolimus blood trough level (TL).
time frame: from screening to months 6
number of dose adjustment
time frame: from screening to months 6
Occurrence of treatment failure
time frame: from screening to months 6
Delayed graft function
time frame: from screening to months 6
Acute rejection requiring treatment
time frame: from screening to months 6
Consumption of concomitant immunosuppressant medications
time frame: from screening to months 6
Treatment discontinuation
time frame: from screening to months 6

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Patient's signed informed consent obtained prior to any study-related procedure; 2. Adult men and women at least 18 years of age with end-stage renal disease who are recipients (or will be recipients) of a kidney transplant from a living or deceased donor; 3. No known contraindications to the administration of tacrolimus, other macrolides and study drugs excipients; 4. Patients must agree to use a highly reliable method of birth control; 5. Donor-recipient negative cross match test, and compatible AB0 blood type; 6. Able to swallow tablets and capsules Exclusion Criteria: 1. Recipient of any transplanted organ other than kidney; 2. Recipient of a previous renal transplant; 3. Recipient of a kidney from a donor after cardiac death; 4. Recipient of a kidney from an AB0 incompatible or positive cross-match donor; 5. Current (not older than 3 months) anti-HLA Panel Reactive Antibody (PRA) levels higher than 30%. Whenever PRA, either complement-dependent cytotoxicity-PRA or calculated PRA , is not available, patients who are positive on solid-phase screening assay for anti-HLA antibodies must not be enrolled; 6. Recipient of a kidney with a cold ischemia time of ≥ 30 hours; 7. White blood cells count ≤ 2.8x109 cells/L unless ANC >1.0x109/L; 8. Platelet count < 50 x109 cells/L; 9. ALT or AST levels >3 times the normal upper limit during the 30 days prior transplant procedure; 10. Current abuse of drugs or alcohol; 11. Incapable of understanding purpose and risk of study, unable to give written informed consent or unwilling to comply with study protocol; 12. Treatment with any other investigational agent in the 30 days prior to enrolment; 13. Kidney recipients and/or donors positive for HCV (HCV-RNA positive or HCV-Ab positive respectively); 14. Kidney recipients and/or donors positive for HBV (HBV-DNA or HBS-Ag positive); 15. Recipients positive for HIV; 16. Patient or donor with current diagnosis or history of malignancy within the past 5 years except basal or non-metastatic squamous cell carcinoma of the skin successfully treated; 17. Uncontrolled concomitant infection, systemic infection requiring treatment or any other unstable condition that could interfere with study objectives; 18. Severe diarrhoea, vomiting, active peptic ulcer or GI disorder that may affect absorption of tacrolimus; 19. Known hypersensitivity to tacrolimus other macrolides and study drugs excipients; 20. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS are willing to use reliable methods of contraception

Additional Information

Official title Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
Principal investigator Klemens Budde, MD
Description This is a Multicentre, Open label, Randomized, Two-arm, parallel-group study to assess efficacy and safety of Envarsus® compared with tacrolimus used as per current clinical practice in the initial maintenance setting in de novo kidney transplant patients. The study will be conducted in approximately 10 european countries.
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Chiesi Farmaceutici S.p.A..